IlluminaXTER:ILU +0.60%76 Net Margin % is 12.28% as of Mar. 2026, which is 37% below its 10-year median of 19.44. GuruFocus rates XTER:ILU with a GF Score™ of 76/100 and a GF Value™ of €91.68 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, Illumina ranks better than 91.67% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Illumina's Net Income for the
three
months ended in Mar. 2026 was €116 Mil. Illumina's Revenue for the
three
months ended in Mar. 2026 was €944 Mil. Therefore, Illumina's net margin for the quarter that ended in Mar. 2026 was 12.28%.
The historical rank and industry rank for Illumina's Net Margin % or its related term are showing as below:
XTER:ILU'
s Net Margin % Range Over the Past 10 Years
Min: -96.07 Med: 19.44 Max: 28.28
Current: 19.42
XTER:ILU's Net Margin % is ranked better than 91.67% of 204
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.405
vs XTER:ILU: 19.42
Illumina (XTER:ILU) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Illumina Net Margin % Related Terms
Illumina Net Margin % Historical Data
* Premium members only.
The historical data trend for Illumina's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Illumina's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Illumina Net Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Illumina's Net Margin % distribution charts can be found below:
* The bar in red indicates where Illumina's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Illumina (XTER:ILU) has a Net Margin % of 12.28% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Illumina and its competitors. This is 37% below median its historical median of 19.44. According to the industry distribution chart, Illumina ranks #17 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 8.3%.
Is Illumina's Net Margin % too high?
Illumina's current Net Margin % of 12.28% is 37% below median its 10-year median of 19.44. Based on the distribution chart, Illumina ranks #17 out of 204 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Illumina has a GF Score™ of 76/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Illumina's Net Margin % compare to MTD and DGX?
According to the Medical Diagnostics & Research industry distribution chart, Illumina ranks #17 out of 204 companies for Net Margin %. This places Illumina in the top 8% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Diagnostics & Research company?
A good Net Margin % depends on the Medical Diagnostics & Research industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Illumina and its competitors. Illumina's current Net Margin % is 12.28%, which is 37% below median its own 10-year median of 19.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Illumina stock overvalued right now?
Based on GuruFocus' analysis, Illumina (XTER:ILU) is currently considered Significantly Overvalued. The stock's GF Value™ is €91.68, compared to a current price of €124.28 — trading 35.6% above its estimated fair value. The current Net Margin % is 12.28%, which is 37% below median its 10-year median of 19.44. Illumina's overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Illumina (XTER:ILU), the current Net Margin % is 12.28% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Illumina (XTER:ILU) Overvalued in 2026?
Based on GuruFocus' analysis, Illumina stock appears to be overvalued.
The current stock price of €124.28 is trading 35.6% above its estimated GF Value™ of €91.68.
GuruFocus considers Illumina to be Significantly Overvalued.
Key valuation signals for XTER:ILU:
Net Margin %: 12.28% (37% below median its 10-year median of 19.44)
GF Value™: €91.68 vs. price of €124.28 (35.6% above fair value)
No single metric tells the full story. See the XTER:ILU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
76GF Score
Get the complete analysis for XTER:ILU
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTER:ILU has been successfully added to your 
